Sponsor

Clinical trials sponsored by Regeneron Pharmaceuticals

Active studies whose public registry record names Regeneron Pharmaceuticals as lead sponsor.

6active studies

4recruiting now

3countries represented

60largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Overweight or ObesityCondition

Olatorepatide, PlaceboTreatment

United States5 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-08-20 · NCT07685808See eligibility →

Recruiting nowPhase 2

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Condition

ALN-PNP, TirzepatideTreatment

United States6 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-08-10 · NCT07527910See eligibility →

Recruiting nowPhase 1

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

Overweight or ObesityCondition

REGN20934, PlaceboTreatment

United States1 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-07-07 · NCT07594093See eligibility →

Recruiting nowPhase 3

A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

Monogenic ObesityCondition

MibavademabTreatment

Germany1 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-03-10 · NCT07220772See eligibility →

Active, not recruitingPhase 2

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

ObesityCondition

Trevogrumab-Part A, Trevogrumab-Part B and Part CTreatment

Puerto Rico, United States60 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-09-01 · NCT06299098See eligibility →

Active, not recruitingPhase 2

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Overweight or ObesityCondition

Olatorepatide, PlaceboTreatment

United States3 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-06-17 · NCT07431086See eligibility →

Related sponsors

Novo Nordisk A/S71 Eli Lilly and Company67 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.